Advances in Anticancer Agents

Dear Colleagues,

Despite the enormous progress made in the last decade, many types of cancer lack effective therapeutic options. According to the World Health Organization, worldwide, 8 million human deaths per year (around 13% of all deaths) are caused by cancer. Therefore, new anticancer agents and novel strategies for their applications are being intensively developed and tested. It is becoming increasingly clear that a comprehensive approach is needed to overcome this obstacle. In addition to the cytostatic effect of anticancer drugs, it is necessary to target tumor proliferation and metastatic activity. Currently, several natural and synthetic agents with promising biological effects (e.g., the reduction of tumor invasiveness, aggressivity, and cancer risk) have been prepared and tested. However, their therapeutic effectivity can be strongly reduced by their pharmaceutically important properties, such as low solubility, cellular uptake chemical stability, or significant side effects and limited therapeutic effectivity. Nevertheless, their target transportation capabilities, formulations, and combination with other therapeutic regimens can be used to overcome some of these obstacles.

This Special Issue on “Advances in Anticancer Agents” aims to curate novel advances in the design, preparation/formulation, study, and application of natural and synthetic compounds to address longstanding challenges in their development and therapeutic applications. Topics include, but are not limited to, the following:

• The design and study of molecular mechanisms of anticancer agents;
• Strategy for the improvement of the therapeutic effectivity of anticancer agents;
• Advantages and limitations of low/very low toxicity compounds for the prevention of oncological diseases;
• The development and therapeutic applications of synthetic and natural compounds for adjuvant and neoadjuvant therapy.

Dr. Zdenek Kejik
Dr. Michal Masarik 
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Processes is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.